Smith & Nephew posts solid Q1 2026 growth and launches $500m buyback
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Smith & Nephew Snats ( (SNN) ) has provided an update.
On 6 May 2026, Smith & Nephew reported first-quarter 2026 revenue of $1.50 billion, up 3.1% on an underlying basis and 6.6% reported, with growth across all business units and regions despite one fewer trading day. Sports Medicine & ENT led performance, with Sports Medicine now larger than Orthopaedic Reconstruction and Robotics, while US knee implants remained soft and ENT revenue in China was deliberately reduced as the company prepared for volume-based procurement.
Advanced Wound Management delivered solid growth, with strong foam dressing sales and new product launches offsetting pressure from a U.S. reimbursement reset for skin substitutes, which is weighing on volumes and pricing but remains in line with expectations. Management kept full-year 2026 guidance unchanged, projecting mid-single-digit revenue growth, higher trading profit and robust free cash flow, and underlined confidence in its new RISE strategy and innovation-led growth by announcing a $500 million share buyback alongside the recent acquisition and integration of Integrity Orthopaedics.
The most recent analyst rating on (SNN) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew is a global medical technology company focused on orthopaedics, sports medicine and ear, nose and throat (ENT) products, as well as advanced wound management solutions. Its portfolio includes joint repair implants, arthroscopic enabling technologies and wound care, bioactive and device platforms serving hospitals and other healthcare providers worldwide.
Average Trading Volume: 923,191
Technical Sentiment Signal: Hold
Current Market Cap: $13.24B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.
